The World Health Organization declared the rapid cross-border surge of Bundibugyo ebolavirus across the Democratic Republic of the Congo and Uganda a Public Health Emergency of International Concern.
Key Facts: Medical and Global Dynamics of Bundibugyo Ebolavirus
Pathogen Classification: Bundibugyo ebolavirus is a highly lethal, single-stranded RNA virus belonging to the genus Orthoebolavirus (family Filoviridae) that causes severe viral hemorrhagic fever in humans.
Zoonotic Reservoir: Fruit bats are the suspected natural reservoir hosts of the virus. Spillover into humans occurs through zoonotic exposure, followed by direct person-to-person transmission via infected blood, bodily fluids, or contaminated surfaces.
Lack of Cross-Protection: The ebolavirus genus includes multiple distinct species such as Zaire, Sudan, Bundibugyo, and Taï Forest. Immunity or vaccination against one species does not provide cross-protection against others due to significant structural differences in surface glycoproteins.
Vaccine and Treatment Gap: Unlike Zaire ebolavirus—which has licensed vaccines (Ervebo, Zabdeno/Mvabea) and US FDA–approved treatments—Bundibugyo ebolavirus currently has no licensed vaccines or species-specific therapeutic interventions.
Containment Standards (BSL-4): Handling or culturing live ebolaviruses requires Biosafety Level 4 (BSL-4) facilities featuring negative air pressure, positive-pressure protective suits, and independent redundant HEPA-filtered air systems.
Neglected Tropical Disease (NTD) Status: Bundibugyo virus aligns with the characteristics of neglected tropical diseases, disproportionately affecting marginalized populations in low-income tropical regions and facing chronic market failure due to limited commercial incentives for billion-dollar vaccine development.
Profile
Settings
Refer your friends
Sign out
